AtriCure reports preliminary Q4 revenue $124.3M (+17%); guides 2025 revenue $517-527M

AtriCure, Inc.

2024-FY EPS reported -$0.95 revenue$465,307,000

Preliminary Q4 2024 revenue $124.3M (+17% YoY as reported and constant currency).
U.S. revenue $101.6M (+14%), international $22.7M (+28%) in Q4.
FY2024 revenue $465.3M (+17%); expects adj. EBITDA $26M-$29M and adj. EPS loss $0.74-$0.80.
2025 guidance: revenue $517M-$527M, adj. EBITDA $40M-$44M, modest cash flow generation.
Analyst & Investor Day scheduled for March 26, 2025 at Mason, Ohio headquarters.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.